Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prostate brachytherapy: a descriptive analysis from CaPSURE.

W Robert Lee1, Jerrold Sharkey, Janet E Cowan

  • 1Department of Radiation Oncology, Duke University School of Medicine, Duke University Medical Center, Durham, NC 27710, USA. w.robert.lee@duke.edu

Brachytherapy
|April 17, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A High Decipher Genomic Risk Score Is Associated with Major Pathological Progression in Patients Undergoing Active Surveillance for Prostate Cancer.

European urology oncology·2026
Same author

Generative Artificial Intelligence Successfully Automates Data Extraction From Unstructured Magnetic Resonance Imaging Reports: Feasibility in Prostate Cancer Care.

JCO clinical cancer informatics·2026
Same author

Development and Validation of a Generative Artificial Intelligence-Based Pipeline for Automated Clinical Data Extraction From Electronic Health Records: Technical Implementation Study.

JMIR bioinformatics and biotechnology·2026
Same author

Correlation of unfavourable and favourable histology at radical prostatectomy with Decipher scores and freedom from biochemical recurrence.

Histopathology·2025
Same author

Clinical Comparison of Decipher 1.0 and 1.1 for Localized Prostate Cancer: Results in Prostatectomy and Active Surveillance Patients.

European urology oncology·2025
Same author

Determining Optimal Patient Selection for High-intensity Focused Ultrasound for Prostate Cancer.

European urology focus·2025
Same journal

EM-tracked MR-US live fusion and needle location in gynecologic brachytherapy.

Brachytherapy·2026
Same journal

Contour and dosimetric evaluation of an in-room mobile CBCT scanner for cylinder based brachytherapy.

Brachytherapy·2026
Same journal

Brachytherapy for rectal cancer: An overview of clinical competency development in contemporary practice.

Brachytherapy·2026
Same journal

Deep learning-based automatic segmentation of rectal tumors in endoscopic images.

Brachytherapy·2026
Same journal

Online educational program for CT-based image-guided adaptive brachytherapy in cervical cancer: The BrachyAcademy experience.

Brachytherapy·2026
Same journal

On the surface of excellence: Core competencies for successful skin and superficial brachytherapy.

Brachytherapy·2026
See all related articles

Prostate brachytherapy (PB) with supplemental external beam (SEB) radiation therapy is increasingly used for higher-risk prostate cancer. Isotope choice in PB depends on patient and disease factors, not treatment trends.

Area of Science:

  • Oncology
  • Radiation Oncology
  • Urologic Oncology

Background:

  • Prostate brachytherapy (PB) is a common treatment for prostate cancer.
  • Supplemental external beam (SEB) radiation therapy may be used with PB for higher-risk disease.
  • Understanding factors influencing treatment decisions is crucial for optimizing patient outcomes.

Purpose of the Study:

  • To describe patient and disease characteristics in a large prostate cancer registry of men treated with PB.
  • To identify factors associated with the use of SEB in conjunction with PB.
  • To examine factors influencing the choice of radioactive isotope for PB.

Main Methods:

  • Analysis of data from the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) registry.

Related Experiment Videos

  • Inclusion of 791 men diagnosed with prostate cancer between 1990 and 2003, treated with PB (alone or with SEB).
  • Examination of patient demographics, disease characteristics, and year of diagnosis to determine associations with SEB use and isotope selection.

    • Main Results:

    • SEB use was associated with higher pretreatment PSA, T-stage, and Gleason score, indicating its use in higher-risk prostate cancer.
    • SEB use increased significantly over the study period, particularly after 1999.
    • Isotope choice (I-125 vs. Pd-103) was linked to patient demographics (age, education, wealth, insurance) and disease characteristics (T-stage, Gleason score, risk category).

    Conclusions:

    • The use of SEB in prostate brachytherapy is driven by disease characteristics and has increased over time.
    • Isotope selection for prostate brachytherapy is influenced by a combination of patient and disease factors.
    • These findings aid in understanding treatment patterns and guiding future therapeutic decisions in prostate cancer management.